Clinical evaluation on efficacy of domestic nateglinide tablet in patients with type 2 diabetes mellitus

Abstract

Abstract: AIM: To evaluate the efficacy of domestic nateglinide tablet with the treatment of patients with type 2 diabetes mellitus (T2DM).METHODS: Forty-six patients of T₂DM were included in this study.The twentythree patients in nateglinide group took nateglinide tablet, and another twenty-three patients in the repaglinide group took repaglinide tablet.The changes of both fasting blood glucose and hemoglobin A_1C(HbA_1C)levels were assayed. RESULTS: After the treatment of 12 weeks, the levels of fasting blood glucose and HbA1C decreased significantly (P<0.01).After 8th weeks, the levels of fasting blood glucose of repaglinide group on finger-tip decreased significantly than those of the nateglinide group.CONCLUSION: Domestic nateglinide, as an effective and safe agent, can improve the glycometabolism in treating T₂DM.

Key words: nateglinide tablet, repaglinide tablet, hemoglobin A_1C, type 2 diabetes mellitus, fasting blood glucose

CLC Number:

XIA Li-Bin, LU Mei-Qin, ZHANG Bin-Hua, ZHANG An-Su, CHEN Yue-Ping, HUA Qiang, MAO Guo-Guang. Clinical evaluation on efficacy of domestic nateglinide tablet in patients with type 2 diabetes mellitus[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(8): 932-934.

References

1 吴万玲.快速胰岛素促泌降糖作用评价[J].国外医学内分泌学分册, 2002;22(3):154
2 廖二元, 超楚生, 主编.内分泌学[M].北京:人民卫生出版社, 2001:1442
3 梁慧芬.内分泌与代谢疾病用药指南[M].美迪医讯亚太有限公司, 2003:170-2
4 Whitelaw DC, Clark PM, Smith JM, Nattrass M.Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus[J].DiabetMed, 2000;17(3):225-9
5 Barnett AH, Anderson DM, Shelley S, Morgan R, Owens DR. A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes[J].Diabetes Obes Metab, 2004;6(2):104-13
6 Gribble FM, Manley SE, Levy JC.Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166)[J].Diabetes Care, 2001;24(7):1221-5
7 Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE.Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control[J].Diabetes Care, 2003;26(6):1685-90
8 Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S.Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes[J].Diabetes Care, 2000;23(11):1660-5
9 Mary F, Carroll, Ahmad I, Katrina R, Mark R, Burge, et al. Control of postprandial hyperglycemia optimal use of short-acting insulin secretagogues[J].Diabetes Care, 2002;25:2147-52
10 Saloranta C, Hershon K, BallM, Dickinson S, Holmes D.Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia[J].Clin Endocrinol Metab, 2002;87(9):4171-6
11 Stefano Del Prato, Robert J, Heine, Leonard K, Christiane G, Sharon G, et al.Emmons treatment of patients over 64 years of age with type 2 diabetes experience from nateglinide pooled database retrospective analysis[J].Diabetes Care, 2003;26(7):2075-80

[1]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[2]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[3]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[4]	LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
[5]	DAI Hongyu, YANG Kun, HU Ruchun, ZHOU Hongmei, MA Peimin, HAO Qian. Duration time and effectiveness of 0.25%ropivacaine for sciatic nerve block in patients with diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1278-1284.
[6]	XU Yongxia, XIE Mingzhu, GONG Muxue, HUANG Jiaying, ZHAO Li, ZHU Defa. Effects of 25(OH)D on islet β-cells function in the elderly with type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1021-1026.
[7]	ZHAO Hailing, ZHANG Haojun, ZHAO Tingting, YAN Meihua, DONG Xi, MA Liang, LI Ping. Association between the polymorphism of PNPLA2 gene and the risk of ischemic stroke in type 2 diabetic patients in Chinese Han Population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 664-669.
[8]	YE Shengkai, WEN Jie, LIU Weiping, REN Xia, CHEN Haiying, DU Ying, LI Xue, ZHANG Ru, YU Li, ZHANG Biying. Effects of dapagliflozin on intima-medial thickness of carotid artery in type 2 diabetic mellitus patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 814-819.
[9]	ZHANG Chunyan, FAN Xiaodong, QIN Yuan, KONG Wenqiang, ZHOU Chunyang, DU Biao. Markov model to assess long-term effects of teneligliptin in treatment of type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 65-72.
[10]	SONG Meiqing. Effect of metformin on bone mineral density, insulin resistance and cytokines in type 2 diabetes mellitus patients with primary hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 694-698.
[11]	LIU Chang, JIANG Daoli, LIU Xiaofang, XU Jia, WANG Lijue, WANG Qian, XU Ling, FANG Yi. Establishment of rat model of type 2 diabetes induced by streptozotocin combined with cerebral ischemic reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 518-525.
[12]	NI Yingqun, XIE Fengtao, FANG Zhaohui. Danzhijiangtang capsule protects vasculopathy of T2DM: an evaluation based on the expression of Wnt/β-catenin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 531-537.
[13]	WANG Chanyue, WANG Ye, ZHANG Peipei, CHEN Mingyue, YANG Hao, ZHU Manli, LI Linlin. Relationship of Fusobacterium nucleatum levels in gut microbiota with type 2 diabetes mellitus in Uygurs of Xinjiang [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1321-1325.
[14]	KONG Xiang, HUA Qiang, MENG Xiangjian, YAO Xinming, WANG Yong, XIA Libin. Clinical implications of circulating miRNA-101 expression level in patients with newly diagnosed type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1406-1409.
[15]	DONG Chao, WANG Tao, ZHOU Dongmei, WANG Ya, WANG Laicheng, LV Dongmei. Investigation and analysis of antidiabetic agents therapy in inpatients with type 2 diabetes mellitus in our hospital [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 87-91.